Market Closed -
Nasdaq
04:00:00 2024-05-17 pm EDT
|
5-day change
|
1st Jan Change
|
0.37
USD
|
-4.05%
|
|
-4.27%
|
+24.75%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
21.48
|
535.1
|
255
|
73.82
|
38.09
|
47.52
|
-
|
-
|
Enterprise Value (EV)
1 |
21.48
|
535.1
|
255
|
76.18
|
38.09
|
20.32
|
2.02
|
17.22
|
P/E ratio
|
-80.6
x
|
-27.8
x
|
-25.6
x
|
-2.17
x
|
-0.63
x
|
-1.12
x
|
-1.33
x
|
-1.87
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
2,598
x
|
353
x
|
156
x
|
58.2
x
|
153
x
|
8.74
x
|
1.21
x
|
EV / Revenue
|
-
|
2,598
x
|
353
x
|
161
x
|
58.2
x
|
65.2
x
|
0.37
x
|
0.44
x
|
EV / EBITDA
|
-
|
-
|
-
|
-1.61
x
|
-0.98
x
|
-0.45
x
|
-0.03
x
|
-0.53
x
|
EV / FCF
|
-
|
-
|
-
|
-1.72
x
|
-
|
-0.49
x
|
-0.04
x
|
-1.13
x
|
FCF Yield
|
-
|
-
|
-
|
-58%
|
-
|
-202%
|
-2,811%
|
-88.3%
|
Price to Book
|
-
|
-
|
-
|
20
x
|
-
|
1.54
x
|
1.61
x
|
1.85
x
|
Nbr of stocks (in thousands)
|
2,049
|
59,393
|
62,204
|
73,820
|
128,416
|
128,434
|
-
|
-
|
Reference price
2 |
10.48
|
9.010
|
4.100
|
1.000
|
0.2966
|
0.3700
|
0.3700
|
0.3700
|
Announcement Date
|
9/10/20
|
3/29/21
|
3/11/22
|
3/13/23
|
3/13/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
0.206
|
0.723
|
0.473
|
0.654
|
0.3115
|
5.44
|
39.31
|
EBITDA
1 |
-
|
-
|
-
|
-47.39
|
-38.84
|
-44.7
|
-58.95
|
-32.65
|
EBIT
1 |
-16.33
|
-20.21
|
-49.98
|
-48.41
|
-40.54
|
-40.6
|
-47.44
|
-36.38
|
Operating Margin
|
-
|
-9,812.62%
|
-6,912.59%
|
-10,234.46%
|
-6,198.78%
|
-13,033.92%
|
-872.06%
|
-92.54%
|
Earnings before Tax (EBT)
1 |
-
|
-18.87
|
-10.17
|
-29.92
|
-49.5
|
-44.86
|
-47.76
|
-35.62
|
Net income
1 |
-
|
-19.28
|
-9.74
|
-29.92
|
-49.5
|
-44.86
|
-47.76
|
-35.62
|
Net margin
|
-
|
-9,357.77%
|
-1,347.16%
|
-6,325.16%
|
-7,569.42%
|
-14,402.25%
|
-877.95%
|
-90.62%
|
EPS
2 |
-0.1300
|
-0.3238
|
-0.1600
|
-0.4600
|
-0.4700
|
-0.3300
|
-0.2780
|
-0.1975
|
Free Cash Flow
1 |
-
|
-
|
-
|
-44.19
|
-
|
-41.1
|
-56.8
|
-15.2
|
FCF margin
|
-
|
-
|
-
|
-9,342.49%
|
-
|
-13,194.22%
|
-1,044.12%
|
-38.67%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
9/10/20
|
3/29/21
|
3/11/22
|
3/13/23
|
3/13/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
0.199
|
0.03
|
0.035
|
0.174
|
0.234
|
0.107
|
0.269
|
0.108
|
0.17
|
0.073
|
0.075
|
0.0775
|
0.13
|
0.1
|
0.1
|
EBITDA
1 |
-
|
-13.14
|
-13.31
|
-9.572
|
-11.37
|
-10.33
|
-9.894
|
-9.103
|
-9.508
|
-8.812
|
-10.5
|
-11.7
|
-13.3
|
-
|
-
|
EBIT
1 |
-14.06
|
-13.34
|
-13.6
|
-9.805
|
-11.67
|
-10.73
|
-10.34
|
-9.542
|
-9.93
|
-9.232
|
-9.549
|
-9.771
|
-9.999
|
-8.9
|
-8.9
|
Operating Margin
|
-7,064.32%
|
-44,453.33%
|
-38,842.86%
|
-5,635.06%
|
-4,988.46%
|
-10,029.91%
|
-3,842.38%
|
-8,835.19%
|
-5,841.18%
|
-12,646.58%
|
-12,732%
|
-12,607.74%
|
-7,691.54%
|
-8,900%
|
-8,900%
|
Earnings before Tax (EBT)
1 |
4.208
|
-13.35
|
-4.534
|
-10.98
|
-1.054
|
-11.77
|
-25.14
|
-2.418
|
-10.17
|
-11.08
|
-10.61
|
-11.33
|
-11.81
|
-9
|
-9
|
Net income
1 |
4.423
|
-13.35
|
-4.534
|
-10.98
|
-1.054
|
-11.77
|
-25.14
|
-2.418
|
-10.17
|
-11.08
|
-10.61
|
-11.33
|
-11.81
|
-9
|
-9
|
Net margin
|
2,222.61%
|
-44,513.33%
|
-12,954.29%
|
-6,308.05%
|
-450.43%
|
-11,000%
|
-9,346.84%
|
-2,238.89%
|
-5,984.12%
|
-15,178.08%
|
-14,152%
|
-14,617.64%
|
-9,087.69%
|
-9,000%
|
-9,000%
|
EPS
2 |
0.0700
|
-0.2100
|
-0.0700
|
-0.1700
|
-
|
-0.1500
|
-0.2900
|
-0.0200
|
-0.0600
|
-0.0900
|
-0.0800
|
-0.0867
|
-0.0767
|
-0.0700
|
-0.0700
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/11/22
|
5/9/22
|
8/15/22
|
11/7/22
|
3/13/23
|
5/12/23
|
8/14/23
|
11/7/23
|
3/13/24
|
5/8/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
2.36
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
27.2
|
45.5
|
30.3
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-0.0497
x
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-44.2
|
-
|
-41.1
|
-56.8
|
-15.2
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-378%
|
-
|
-143%
|
-136%
|
-31.6%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
-
|
0.0500
|
-
|
0.2400
|
0.2300
|
0.2000
|
Cash Flow per Share
2 |
-
|
-
|
-0.6000
|
-
|
-0.2400
|
-0.2200
|
-0.0500
|
Capex
1 |
0.39
|
1.33
|
5.18
|
-
|
2
|
2
|
2
|
Capex / Sales
|
187.86%
|
184.23%
|
1,094.93%
|
-
|
642.05%
|
36.76%
|
5.09%
|
Announcement Date
|
3/29/21
|
3/11/22
|
3/13/23
|
3/13/24
|
-
|
-
|
-
|
Last Close Price
0.37
USD Average target price
5
USD Spread / Average Target +1,251.35% Consensus |
1st Jan change
|
Capi.
|
---|
| +24.75% | 47.52M | | +9.42% | 115B | | +11.84% | 106B | | -1.05% | 21.96B | | -14.15% | 21.87B | | -5.29% | 19.21B | | -4.16% | 18.08B | | -38.29% | 17.71B | | +7.99% | 14.32B | | +36.24% | 12.42B |
Bio Therapeutic Drugs
|